VISN 5 MIRECC - General Publications 2009 - MIRECC / CoE
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.



Quick Links

Veterans Crisis Line Badge
My healthevet badge

VISN 5 MIRECC - General Publications 2009


About Us • Clinical • Education • Research


Bennett, M. E. (2009). Assessment of substance use and substance use disorders in schizophrenia. Clinical Schizophrenia & Related Psychoses, 3(1), 50-63.

Bennett, M. E., Bellack, A. S., Brown, C. H., & DiClemente, C. (2009). Substance dependence and remission in schizophrenia: A comparison of schizophrenia and affective disorders. Addictive Behaviors, 34(10), 806-814.

Bennett, M. E., Nidecker, M., Kinnaman, J. S., Li, L., & Bellack, A. S. (2009). Examination of the Inventory of Drug Use Consequences with Individuals with Serious and Persistent Mental Illness and Co-occurring Substance Use Disorders. American Journal of Drug and Alcohol Abuse, 35(5), 385-390.

Borzekowski, D. L. G., Leith, J., Medoff, D. R., Potts, W., Dixon, L., Balis, T., Hackman, A. L., & Himelhoch, S. (2009). Use of the internet and other media for health information among clinic outpatients with serious mental illness. Psychiatric Services, 60, 1265-1268.

Chander, G., Himelhoch, S., Fleishman, J. A., Hellinger, J., Gaist, P., Moore, R. D., & Gebo, K. A. (2009). HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDs care, 21(5), 655-663.

Conley, R. R., Boggs, D. L., Kelly, D. L., McMahon, R. P., Dickinson, D., Feldman, S., Ball, M. P., & Buchanan, R. W. (2009). The effects of galantamine on psychopathology in chronic stable schizophrenia. Clinical Neuropharmacology, 32(2), 69-74.

Deutsch, S. I., Mastropaolo, J., Burket, J. A., & Rosse, R. B. (2009). An epigenetic intervention interacts with genetic strain differences to modulate the stress-induced reduction of fluazepam’s antiseizure efficacy in the mouse. European Nueropsychopharmacology, 19(6):398-401.

Dickinson, D., & Harvey P. D. (2009). Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophrenia Bulletin, 35(2), 403-414.

Dixon, L., Goldberg, R., Iannone V., Lucksted A., Brown, C., Kreyenbuhl, J., Fang, L., & Potts, W. (2009). Use of a critical time intervention to promote continuity of care after psychiatric inpatient hospitalization for severe mental illness. Psychiatric Services, 60(4), 451-458.

Dixon, L., Medoff, D., Goldberg, R., Lucksted, A., Kreyenbuhl, J., DeiClemete, C., Potts, W., Keith, J., Brown, C., Adams, C., & Afful, J. (2009). Is implmentation of the 5 A's of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness? American Journal of Addictions, 18(5), 386-392.

Drapalski, A. L., Leith, J., & Dixon, L. (2009). Involving families in the care of persons with schizophrenia and other serious mental illnesses: History, evidence, and recommendations. Clinical Schizophrenia and Related Psychosis, 3(1), 39-49.

Gandhi, D., Welsh, C., Bennett, M., Carreño, J., & Himelhoch, S. (2009). Acceptability of Technology-based Methods Substance Abuse Counseling in Office Based Buprenorphine Maintenance for Opioid Dependence. American Journal on Addictions, 18(2), 182-183.

Goldberg, R., Tapscott, S., Calmes, C., & Wolfe, R. (2009). HIV and hepatitis knowledge among individuals with serious mental illness. Psychiatric Rehabilitation Journal, 33, 375-377.

Harvey, P. D., & Bellack, A. S. (2009). Toward a Terminology for Functional Recovery in Schizophrenia: Is Functional Remission a Viable Concept? Schizophrenia Bulletin, 35(2), 300-306.

Himelhoch, S., Leith, J., Goldberg, R., Kreyenbuhl, J., Medoff, D., & Dixon, L. (2009). Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smoke. General Hospital Psychiatry, 31(1), 30-32.

Himelhoch, S., McCarthy, J., Gonaczy, D., Medoff, D., Kilbourne A., Goldberg, R., Dixon, L., & Blow, F. (2009). Understanding associations between serious mental illness and hepatitis C among veterans: a national multivariate analysis. Psychsomatics, 50(1), 30-37.

Hong, L. E., Turano, K. A., O’Neill, H. B., Hao, L., Wonodi, I., McMahon, R. P., & Thaker, G. K. (2009). Is motion perception deficit in schizophrenia a consequence of an eye-tracking abnormality. Biological Psychiatry, 65(12), 1079-1085.

Kelly, D. L., Buchanan, R. W., Boggs, D. L., McMahon, R. P., Dickinson, D., Nelson, M., Gold, J. M., Ball, M. P., Feldman, S., Lui, F., & Conley, R. R. (2009). A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. Journal of Clinical Psychiatry, 70(4), 518-525.

Kreyenbuhl, J., Nossell, I. R., & Dixon, L. B. (2009). Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature. Schizophrenia Bulletin, 35(4), 696-703.

Lucksted, A., McNulty, K., Brayboy, L., & Forbes, C. (2009). Initial evaluation of the peer-to-peer program. Psychiatric Services, 60(2), 250-253.

Marx, C. E., Keefe, R. S., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., Savitz, A. J., Leimone, L. A., Dunn, L., Porcu, P., Morrow, A. L., & Shampine, L. J. (2009). Proof of concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology, 34(8), 1885-1903.

McCarthy, J. F., Dixon, L., & Slade E. (2009). In Reply: ACT and other case management services. Psychiatric Services, 60(4), 555-556.

McCarthy, J. F., Valenstein, M., Dixon, L., Visnic S., Blow, F. C., & Slade, E. P. (2009). Initiation of assertive community treatment among veterans with serious mental illness: clients and program factors. Psychiatric Services, 60(2), 196-201.

Mishra, S. I., Lucksted, A., Gioia, D., & Barnet, B. (2009). Needs and preferences for receiving mental health information in an African American focus group sample. Community Mental Health Journal, 45(2), 117-126.

Rowland, L. M., Spieker, E. A., Francis, A., Barker, P. B., Carpenter, W. T., & Buchanan, R. W. (2009). White matter alternation in deficit schizophrenia. Neuropsychopharmacology, 34(6), 1514-1522.

Schwartz, B. L., Parker, E. S., Rosse, R. B., & Deutsch, S. I. (2009). Recognition memory probes affect what is remembered in schizophrenia. Psychiatry Research, 167(1-2), 21-27.

Sherman, M. D., Fischer, E. P., Bowling, U. B., Dixon, L. B., Ridener, L., & Harrison, D. (2009). A new engagement strategy in a VA-based family psychoeducation program. Psychiatric Services, 60(2), 254-257.

Tenhula, W., Bennett, M. E., & Bellack, A. S. (2009). Behavioral Treatment of Substance Use in Schizophrenia. Journal of Clinical Psychology, 65(8), 831-841.

Wonodi, I., Hong, L. E., Stine, O. C., Mitchell, B. D., Elliott, A., Roberts, R. C., Conley, R. R., McMahon, R. P., & Thaker, G. K. (2009). Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 150B(2), 282-289.


NOTE: Names in bold are VISN 5 MIRECC Investigators